Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Response Surface Modeling of Remimazolam and Sevoflurane

27 maj 2026 uppdaterad av: Kim Hee Young, Pusan National University Yangsan Hospital

Response Surface Model Between Remimazolam and Sevoflurane; Comparison of the Minto and the Greco Model

This prospective randomized open-label study aims to investigate the pharmacodynamic interaction between remimazolam and sevoflurane during general anesthesia using response surface modeling. Although remimazolam has favorable hemodynamic stability compared with propofol, its hypnotic effect may be less predictable and poorly correlated with conventional sedation monitoring indices such as the bispectral index (BIS). In clinical practice, remimazolam and sevoflurane are often combined during induction and maintenance of anesthesia; however, the optimal interaction between these agents remains unclear.

This study will evaluate whether the interaction between remimazolam and sevoflurane is synergistic, additive, or infra-additive using two representative response surface interaction models: the Minto model and the Greco model. BIS values and predicted effect-site concentrations will be analyzed using NONMEM software.

Studieöversikt

Detaljerad beskrivning

Remimazolam is a recently developed ultra-short-acting benzodiazepine anesthetic with favorable pharmacokinetic characteristics, including a short context-sensitive decrement time and relatively stable hemodynamics. Despite these advantages, remimazolam may exhibit weaker hypnotic potency and inconsistent correlations with conventional anesthetic depth monitors such as BIS.

In current clinical practice, anesthesiologists frequently combine remimazolam with volatile anesthetics such as sevoflurane during induction or maintenance of anesthesia. However, the pharmacodynamic interaction between remimazolam and sevoflurane has not been fully elucidated.

The present study will investigate the interaction between remimazolam and sevoflurane using response surface modeling. The study will enroll adult patients undergoing elective laparoscopic surgery under general anesthesia. Various combinations of remimazolam infusion rates and end-tidal sevoflurane concentrations will be administered during anesthetic induction. BIS values and predicted effect-site concentrations will be collected and analyzed.

Pharmacodynamic interaction analyses will be performed using NONMEM nonlinear mixed-effects modeling software. Both the Minto interaction model and the Greco interaction model will be applied to determine whether the interaction between remimazolam and sevoflurane is synergistic, additive, or infra-additive.

Studietyp

Interventionell

Inskrivning (Beräknad)

80

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Hee Young Kim, MD, PhD
  • Telefonnummer: 82-55-360-2129
  • E-post: anekhy@gmail.com

Studieorter

      • Yangsan, Sydkorea, 50612
        • Rekrytering
        • Pusan National University Yangsan Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Adults aged 20 to 80 years
  • Scheduled for elective surgery under general anesthesia at Pusan National University Yangsan Hospital
  • American Society of Anesthesiologists (ASA) physical status I or II
  • Able to provide written informed consent

Exclusion Criteria:

  • Known allergy to remimazolam or sevoflurane
  • Renal, hepatic, neuromuscular, or neurological disease
  • Use of medications affecting the central nervous system
  • Chronic psychoactive drug use
  • Ischemic heart disease
  • Pregnant women

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Remimazolam and Sevoflurane Combination During Anesthetic Induction
Participants undergoing elective surgery under general anesthesia will receive varying combinations of remimazolam and sevoflurane during anesthetic induction to evaluate pharmacodynamic interactions using response surface modeling.
Remimazolam will be administered at infusion rates ranging from 0 to 6 mg/kg/h using an infusion pump with pharmacokinetic simulation software.
Sevoflurane will be administered by inhalation with targeted end-tidal concentrations between 0 and 2 vol%.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Interaction coefficient (α) between remimazolam and sevoflurane derived from the Minto response surface model
Tidsram: During anesthetic induction
The interaction coefficient (α) describing the pharmacodynamic interaction between remimazolam effect-site concentration and end-tidal sevoflurane concentration will be estimated using the Minto response surface model based on BIS values collected during anesthetic induction.
During anesthetic induction
Interaction parameter between remimazolam and sevoflurane derived from the Greco response surface model
Tidsram: During anesthetic induction
The pharmacodynamic interaction parameter describing the interaction between remimazolam effect-site concentration and end-tidal sevoflurane concentration will be estimated using the Greco response surface model based on BIS values collected during anesthetic induction.
During anesthetic induction

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
BIS response according to hypnotic combinations
Tidsram: During anesthetic induction
Bispectral Index (BIS) values will be continuously recorded during anesthetic induction according to predefined combinations of remimazolam effect-site concentration and end-tidal sevoflurane concentration. The BIS is a processed electroencephalographic monitoring scale ranging from 0 to 100, where lower values indicate deeper levels of hypnosis and higher values indicate lighter levels of sedation or consciousness.
During anesthetic induction
Loss of consciousness (LOC)
Tidsram: During anesthetic induction
Time to loss of consciousness during induction
During anesthetic induction
Recovery of consciousness (ROC)
Tidsram: During emergence from anesthesia
Time to recovery of consciousness
During emergence from anesthesia
Heart rate
Tidsram: Intraoperative period
Heart rate (beats per minute) will be recorded at 5-minute intervals during the intraoperative period.
Intraoperative period
Systolic blood pressure
Tidsram: Intraoperative period
Systolic blood pressure (mmHg) will be recorded at 5-minute intervals during the intraoperative period.
Intraoperative period
Mean blood pressure
Tidsram: Intraoperative period
Mean blood pressure (mmHg) will be recorded at 5-minute intervals during the intraoperative period.
Intraoperative period
Cardiac output
Tidsram: Intraoperative period
Cardiac output (L/min) will be recorded at 5-minute intervals during the intraoperative period.
Intraoperative period
Cardiac index
Tidsram: Intraoperative period
Cardiac index (L/min/m²) will be recorded at 5-minute intervals during the intraoperative period.
Intraoperative period
Stroke volume variation
Tidsram: Intraoperative period
Stroke volume variation (%) will be recorded at 5-minute intervals during the intraoperative period.
Intraoperative period
Pulse pressure variation
Tidsram: Intraoperative period
Pulse pressure variation (%) will be recorded at 5-minute intervals during the intraoperative period.
Intraoperative period
Peripheral oxygen saturation
Tidsram: Intraoperative period
Peripheral oxygen saturation (%) will be recorded at 5-minute intervals during the intraoperative period.
Intraoperative period

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Hee Young Kim, MD, PhD, Pusan National University Yangsan Hospital, Yangsan, South Korea

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 maj 2026

Primärt slutförande (Beräknad)

1 april 2027

Avslutad studie (Beräknad)

31 december 2027

Studieregistreringsdatum

Först inskickad

14 maj 2026

Först inskickad som uppfyllde QC-kriterierna

27 maj 2026

Första postat (Faktisk)

2 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

27 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • 05-2023-090

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera